Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Cardiovasc Pharmacol ; 65(6): 640-8, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25806612

RESUMO

This study was designed to assess the progression of pulmonary arterial hypertension (PAH) and the effectiveness of therapy using recently investigated echocardiographic parameters. PAH is characterized by the progressive elevation of pulmonary artery pressure and right ventricular hypertrophy and dysfunction, which ultimately results in right-sided heart failure and death. Echocardiography results and invasive measurements of right and left ventricular systolic pressures were compared after 3-week administrations of sildenafil (S group), pimobendan (P group), nicorandil (N group), and their combinations (SP and SPN groups) in male rats with monocrotaline (MCT)-induced pulmonary hypertension (M group) and without this condition (C group). The groups that received pimobendan alone and in combinations (SP and SPN groups) showed improvement in their echocardiographic parameters of systolic function. A significant improvement of diastolic function was achieved in the SPN group. Invasive measurements showed the most significant decreases of right ventricular systolic pressure in the N and SPN groups, and the use of pimobendan resulted in a comparatively low risk of adverse hemodynamic effects (left ventricular systolic pressure). Although our results suggested the attenuation of PAH severity in all treatment groups, PAH could not be reversed.


Assuntos
Hipertensão Pulmonar/tratamento farmacológico , Monocrotalina , Nicorandil/farmacologia , Piridazinas/farmacologia , Citrato de Sildenafila/farmacologia , Vasodilatadores/farmacologia , Disfunção Ventricular Direita/tratamento farmacológico , Função Ventricular Direita/efeitos dos fármacos , Animais , Modelos Animais de Doenças , Quimioterapia Combinada , Hemodinâmica/efeitos dos fármacos , Hipertensão Pulmonar/induzido quimicamente , Hipertensão Pulmonar/fisiopatologia , Hipertrofia Ventricular Direita/tratamento farmacológico , Hipertrofia Ventricular Direita/fisiopatologia , Masculino , Inibidores da Fosfodiesterase 3/farmacologia , Inibidores da Fosfodiesterase 5/farmacologia , Ratos Wistar , Recuperação de Função Fisiológica , Índice de Gravidade de Doença , Disfunção Ventricular Direita/induzido quimicamente , Disfunção Ventricular Direita/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA